Newsletter | March 17, 2020

03.17.20 -- AbCellera And Lilly To Co-Develop Antibody Therapies For Treatment Of COVID-19

  In Vivo Models And In Vitro Assays For Human RSV Infection - Pre-Clinical Antibody, Small Molecule And Vaccine Development

Recent epidemiological data indicates that over 3 million children under the age of 5 are hospitalized due to RSVrelated infections each year, with over 200,000 deaths annually. Despite over 50 years of research, there remains no licensed vaccine product, and disease due to RSV infection remains an unmet medical need. In vitro & in vivo models for RSV vaccine development can provide a critical component in development of anti-RSV antibodies, small molecules, and vaccines.

Industry Insights
Flow Cytometry — A Gateway For Discovering More About Small Vesicles
Article | By Annalise Barnette, Bio-Rad Laboratories, Inc.

Just as good things come in small packages, small vesicles promise big biological impact

Is Your In-House Strategy Ready For Biologic Drug Development Uncertainty?
Article | By John Ward, Thermo Fisher Scientific

A company has to be able to withstand the highs and lows of biologics development. To avoid costly mistakes and wasted efforts, a company must prepare for surprises along the drug development pathway.

In Vivo Models And In Vitro Assays For Human RSV Infection
White Paper | GVK Biosciences

Learn how customized and high quality pre-clinical animal models and ex vivo readouts can support your anti-RSV biologics development from concept all the way to Investigational New Drug status.

Most Popular News
ÄKTA go Chromatography System
GE Healthcare Life Sciences
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.